{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:27:31Z","timestamp":1740108451621,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00296-019-04498-z","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T08:03:22Z","timestamp":1576915402000},"page":"771-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years\u2019 experience of a tertiary pediatric rheumatology center"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-1526","authenticated-orcid":false,"given":"Rahime","family":"Ko\u00e7","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-3068","authenticated-orcid":false,"given":"Hafize Emine","family":"S\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00c7akan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-0055","authenticated-orcid":false,"given":"\u015eerife G\u00fcl","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Tanatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-2480","authenticated-orcid":false,"given":"Figen","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-7387","authenticated-orcid":false,"given":"Nuray","family":"Aktay Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"key":"4498_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633\u2013652","journal-title":"Nat Rev Drug Discov"},{"key":"4498_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M (2015) Anti-TNF therapy: past, present and future. Int Immunol 27:55\u201362","journal-title":"Int Immunol"},{"key":"4498_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907\u20131915","journal-title":"N Engl J Med"},{"key":"4498_CR4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2008.092866","volume":"68","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580\u20131584","journal-title":"Ann Rheum Dis"},{"key":"4498_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","volume":"14","author":"SA Chambers","year":"2005","unstructured":"Chambers SA, Isenberg D (2005) Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14:210\u2013214","journal-title":"Lupus"},{"key":"4498_CR6","doi-asserted-by":"crossref","unstructured":"Matucci A, Nencini F, Maggi E, Vultaggio A. Hypersensitivity reactions to biologics used in rheumatology. Expert Rev Clin Immunol 2019:1\u20139.","DOI":"10.1080\/1744666X.2020.1684264"},{"key":"4498_CR7","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191\u20132201","journal-title":"Arthritis Rheum"},{"key":"4498_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10067-013-2389-x","volume":"33","author":"P Patil","year":"2014","unstructured":"Patil P, Parker RA, Rawcliffe C, Olaleye A, Moore S, Daly N et al (2014) Methotrexate-induced nausea and vomiting in adolescent and young adult patients. Clin Rheumatol 33:403\u2013407","journal-title":"Clin Rheumatol"},{"key":"4498_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","volume":"16","author":"G Ferrara","year":"2018","unstructured":"Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G et al (2018) Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J 16:46","journal-title":"Pediatr Rheumatol Online J"},{"key":"4498_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/acr.23417","volume":"70","author":"JJ Weiner","year":"2018","unstructured":"Weiner JJ, Eudy AM, Criscione-Schreiber LG (2018) How Well do rheumatology fellows manage acute infusion reactions? A pilot curricular intervention. Arthritis Care Res (Hoboken) 70:931\u2013937","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4498_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4498_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3389\/fphar.2019.00965","volume":"10","author":"MC de Camargo","year":"2019","unstructured":"de Camargo MC, Barros BCA, Fulone I, Silva MT, Silveira M, de Camargo IA et al (2019) Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Front Pharmacol 10:965","journal-title":"Front Pharmacol"},{"key":"4498_CR13","first-page":"66","volume":"26","author":"AJ Grillo-Lopez","year":"1999","unstructured":"Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26:66\u201373","journal-title":"Semin Oncol"},{"key":"4498_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/rheumatology\/keu181","volume":"53","author":"V Rocchi","year":"2014","unstructured":"Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A, Bazzichi L et al (2014) Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford) 53:1527\u20131529","journal-title":"Rheumatology (Oxford)"},{"key":"4498_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.anai.2011.11.004","volume":"108","author":"I Puxeddu","year":"2012","unstructured":"Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A et al (2012) Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol 108:123\u2013124","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4498_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12969-018-0234-0","volume":"16","author":"SS Vinod","year":"2018","unstructured":"Vinod SS, Reed AB, Maxwell J, Cron RQ, Stoll ML (2018) Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year. Pediatr Rheumatol Online J 16:16","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04498-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:16:13Z","timestamp":1608423373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4498"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04498-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2019,12,21]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by local ethical committee (Ethics approval number: KAEK\/2019.01.06).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All these patient files were evaluated retrospectively and all patients were anonymous. When the patients admitted to the hospital, the parents\/patients gave a general consent approving anonymous data use for academic purpose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}